Aktionsplan Pieris Pharmaceuticals, Inc.
Erweiterter Zeitplan
Einfaches Diagramm
Über das Unternehmen Pieris Pharmaceuticals, Inc.
Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in human blood plasma and other bodily fluids. Its lead respiratory Anticalin based drug candidate, elarekibep used for the treatment of asthma; and PRS-220, an oral inhaled Anticalin protein targeting connective tissue growth factor for the treatment of idiopathic pulmonary fibrosis. weitere details| IPO date | 2015-04-13 |
|---|---|
| ISIN | US7207951036 |
| Industry | Biotechnology |
| Sector | Health Care |
| Валюта | usd |
| Валюта отчета | usd |
| Сайт | https://www.pieris.com |
| Цена ао | 13.6 |
| Preisänderung pro Tag: | 0% (13.6) |
|---|---|
| Preisänderung pro Woche: | 0% (13.6) |
| Preisänderung pro Monat: | 0% (13.6) |
| Preisänderung über 3 Monate: | 0% (13.6) |
| Preisänderung über sechs Monate: | -18.07% (16.6) |
| Preisänderung pro Jahr: | +7 947.34% (0.169) |
| Preisänderung über 3 Jahre: | +347.37% (3.04) |
| Preisänderung über 5 Jahre: | +264.61% (3.73) |
| Preisänderung seit Jahresbeginn: | 0% (13.6) |
|
|
Unterschätzung
|
Effizienz
|
|||||||||||||||||||||||||||||||||||||
Dividenden
|
Pflicht
|
Wachstumsimpuls
|
|||||||||||||||||||||||||||||||||||||
| Institutionen | Volumen | Aktie, % |
|---|---|---|
| BVF Inc. | 20609863 | 20.83 |
| Lynx1 Capital Management Lp | 9775849 | 9.88 |
| Citadel Advisors Llc | 1189887 | 1.2 |
| Renaissance Technologies, LLC | 1065007 | 1.08 |
| Blackrock Inc. | 1037747 | 1.05 |
| Acadian Asset Management. LLC | 962358 | 0.97 |
| Vanguard Group Inc | 907390 | 0.92 |
| Geode Capital Management, LLC | 761444 | 0.77 |
| CM Management, LLC | 750000 | 0.76 |
| Northern Trust Corporation | 243592 | 0.25 |
| Aufsicht | Berufsbezeichnung | Zahlung | Geburtsjahr |
|---|---|---|---|
| Mr. Stephen S. Yoder J.D. | CEO, President & Director | 744.13k | 1976 (49 Jahre) |
| Mr. Thomas Bures | Senior VP, CFO & Treasurer | 487.5k | 1975 (50 Jahre) |
| Maria Kelman | Executive Director of Investor Relations | N/A | |
| Dr. Shane Olwill Ph.D. | Senior VP & Chief Development Officer | 463.91k | 1976 (49 Jahre) |
| Mr. Prompong Chaikul | Chief Supply Chain Officer | N/A | 1987 (38 Jahre) |
Adresse: United States, Boston. MA, 225 Franklin Street - in Google Maps öffnen, Öffnen Sie Yandex-Karten
Webseite: https://www.pieris.com
Webseite: https://www.pieris.com
